Anti-Avelumab Polyclonal Antibody (AV974024)

Name: Anti-Avelumab Polyclonal Antibody
Brand: abinScience
SKU: AV974024
Price: 168 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

50ug
100ug
1mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue

AV974024

Description

Anti-Avelumab Polyclonal Antibody (AV974024) is a rabbit polyclonal antibody detecting Avelumab in ELISA.

Highlights

●Affinity Purified — Minimal background and high purity for reliable results.

Reactivité des espèces

General

Applications

ELISA

Espèce hôte

Rabbit

Clonalité

Polyclonal

Isotype

IgG

Immunogène

Avelumab

Cible

Rabbit polyclonal to Bavencio.

Spécificité

The product is specific for Avelumab. This antibody serves as an excellent positive control for Avelumab immunogenicity (ADA) assays.

Niveau d'endotoxines

Please contact with the lab for this information.

Pureté

>90% as determined by SDS-PAGE.

Purification

Purified by antigen affinity column.

Numéro d'accès

CAS: 1537032-82-8

Forme

Liquid

Tampon de stockage

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.

Informations d'utilisation du produit

Application	Dilution
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

Stabilité et stockage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Contexte

Avelumab with trade name Bavencio, is an FDA-approved drug to treat Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma. Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). PD-L1 can be highly expressed on certain tumors, which is thought to lead to reduced activation of immune cells (cytotoxic T-cells in particular) that might otherwise recognize and attack the cancer. Inhibition of PD-L1 by Avelumab can remove this inhibitor effect and thereby engender an anti-tumor response. It is one of several ways to block inhibitory signals related to T-cell activation, a more general strategy known as

Note

For research use only.

Images

Reférences

Fiche technique